This article is more than 5 years old. Information may no longer be current.
ISAR-DESIRE 2
Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis 2
Click Here to Manage Email Alerts
Trial determined whether it is preferable to implant a sirolimus-eluting stent or to switch to a paclitaxel-eluting stent in patients who have experienced sirolimuseluting stent treatment failure.
Design: randomized, open-label, active-controlled
Patients: 450
Centers: 2
Country: Germany
RESULTS: No differences were observed between patients assigned to SES (n=225) and those assigned to PES (n=225) in terms of late lumen loss (0.44 mm vs. 0.38 mm; P=.85) at six-to eight-month follow-up, binary restenosis (19.6% vs. 20.6%; P=.69) or target lesion revascularization (16.6% vs. 14.6%; P=.52). Composite rates of death/MI were also similar between the two groups (6.1% vs. 5.8%; P=.86) as well as stent thrombosis (0.4% vs. 0.4%; P>0.99). However, the researchers did observe higher than expected late loss with SES, suggesting that drug resistance on an individual patient level may contribute to SES restenosis.
Published in J Am Coll Cardiol. 2010;doi:10.1016/j.jacc.2010.02.009.
Click here to read more about the ISAR-DESIRE 2 trial.